Adeno-associated Virus Vectors in Gene Therapy Pipeline Analysis, 2024 | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest Approvals, Companies

As per DelveInsight's assessment, globally, about 70+ key pharma and biotech companies are working on 235+ pipeline drugs in the Adeno-Associated Virus (AAV) Vectors in the Gene Therapy landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
" [https://www.delveinsight.com/report-store/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=blog&utm_medium=promotion&utm_campaign=kpr]" report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Adeno-Associated Virus (AAV) Vectors in the Gene Therapy Market.

The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the emerging therapies for the treatment of Adeno-Associated Virus (AAV) Vectors in Gene Therapy and the aggregate therapies developed by major pharma companies.

*
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

*
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn How the Ongoing Clinical & Commercial Activities will Affect the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Therapeutic Segment @ [https://www.delveinsight.com/report-store/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=blog&utm_medium=promotion&utm_campaign=kpr]

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Therapeutics Landscape

There are approx. 70+ key companies which are developing therapies for AAV vectors in gene therapy. Currently, BioMarin Pharmaceutical is leading the therapeutics market with its AAV vectors in gene therapy drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market Include:

4D Molecular therapeutics, Abeona Therapeutics, Adrenas Therapeutics, Adverum Biotechnologies, Alcyone Lifesciences, Amicus Therapeutics, Applied Genetic Technologies, Aruvant Sciences, AskBio/Selecta Biosciences, Asklepios BioPharmaceutical, Aspa therapeutics, Astellas Gene Therapies, Astellas Pharma, Atsena Therapeutics, Audentes therapeutics, AvantiBio, Axovia Therapeutics, Bayer, Biogen, BioMarin Pharmaceutical, Brain Neurotherapy Bio, Inc., BridgeBio Pharma, Capsida Biotherapeutics, Coave therapeutics, Cyprium Therapeutics, DiNAQOR, Eli lilly and company, ESTEVE, Forge Biologics, Freeline therapeutics, Gene Therapy Research Institution Co., Ltd., Gensight Biologics, Gyroscope Therapeutics, Homology medicines, Intas Pharmaceuticals, Jaguar Gene Therapy, LLC, Kriya therapeutics, Lexeo Therapeutics, Libella Gene Therapeutics, LogicBio therapeutics, LYSOGENE, MeiraGTx, Nanoscope Therapeutics, Neurogene, Neurophth, Neurophth Therapeutics, Novartis/ Arctos medical, Novartis/Vedere Bio, Ocugen, Oyster Point pharmaceuticals, Passage Bio, Pfizer, Poseida Therapeutics, Prevail therapeutics, PTC therapeutics, REGENXBIO Inc., Rocket Pharmaceuticals, Sangamo therapeuics, Sanofi/ Sirion therapeutics, Sarepta Therapeutics, Scout Bio therapeutics, Sio Gene Therapies, Solid Biosciences, Spark therapeuics (Roche), StrideBio, Takeda, Taysha Gene Therapies, Tenaya Therapeutics, Ultragenyx Pharmaceutical, uniQure, ViGeneron, Vivet Therapeutics, Voyager Therapeutics, and others.

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Covered in the Report Include:

*
GS010: Gensight Biologics

*
Valoctocogene roxaparvovec: BioMarin Pharmaceutical

*
DTX401: Ultragenyx Pharmaceutical

*
AAV5-RPGR: MeiraGTx

*
Timrepigene emparvovec: Biogen

*
AMT 061: UniQure

*
RGX-314: REGENXBIO

*
SPK-8011: Spark Therapeutics

*
NFS-01: Neurophth

*
GT 005: Gyroscope Therapeutics

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ [https://www.delveinsight.com/sample-request/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=blog&utm_medium=promotion&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Current Treatment Patterns

4. Adeno-Associated Virus (AAV) Vectors in Gene Therapy - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Late Stage Products (Phase-III)

7. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Mid-Stage Products (Phase-II)

8. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Discontinued Products

13. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Product Profiles

14. Key Companies in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market

15. Key Products in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Therapeutics Segment

16. Dormant and Discontinued Products

17. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Unmet Needs

18. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Future Perspectives

19. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Analyst Review

20. Appendix

21. Report Methodology

Download Sample PDF to Explore the Key Offerings of the Report: [https://www.delveinsight.com/sample-request/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=blog&utm_medium=promotion&utm_campaign=kpr]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=adenoassociated-virus-vectors-in-gene-therapy-pipeline-analysis-2024-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-approvals-companies]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.